Verrica Pharmaceuticals develops and commercializes treatments for skin diseases requiring medical intervention. Its lead product, YCANTH (VP-102, cantharidin), is the first and only healthcare-professional-administered therapy approved by the FDA for molluscum contagiosum in patients aged two years and older. YCANTH is also being studied for common warts, with a global Phase 3 program expected to begin U.S. enrollment before the end of 2025. Through a worldwide license with Lytix Biopharma, Verrica is developing VP-315 (ruxotemitide) for basal cell carcinoma, squamous cell carcinoma, and other non-melanoma skin cancers, and it is preparing a Phase 3 program for the compound. Management believes both YCANTH in common warts and VP-315 could each address billion-dollar market opportunities. As of the end of the third quarter, the company held $21.1 million in cash. A newly announced $50 million private placement will retire its OrbiMed debt facility and, combined with existing cash and receivables, is expected to fund operations into mid-2027.

Total raised

$50M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025